122800-01-5

Basic information

• Product Name: 3-AMINO-1-BENZYL-1H-PYRAZOLE-4-CARBONITRILE
• Synonyms: 3-AMINO-1-BENZYL-1H-PYRAZOLE-4-CARBONITRILE
• CAS NO: 122800-01-5
• Molecular Formula: C₁₁H₁₀N₄
• Molecular Weight: 198.23
• Mol File: 122800-01-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 444.421°C at 760 mmHg
• Flash Point: 222.578°C
• Appearance: /
• Density: 1.226g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-AMINO-1-BENZYL-1H-PYRAZOLE-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-1-BENZYL-1H-PYRAZOLE-4-CARBONITRILE(122800-01-5)
• EPA Substance Registry System: 3-AMINO-1-BENZYL-1H-PYRAZOLE-4-CARBONITRILE(122800-01-5)

Safety Data

• Hazardous Substances Data: 122800-01-5(Hazardous Substances Data)

Usage

General Description

3-AMINO-1-BENZYL-1H-PYRAZOLE-4-CARBONITRILE, also known as ABPC, is a chemical compound with the molecular formula C12H11N5. It is a pyrazole derivative with a carbonitrile functional group and an amino group attached to the 3-position of the benzyl ring. ABPC is a versatile intermediate used in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It can also be utilized as a building block in the development of new chemical entities with potential biological activities. ABPC is an important chemical in the field of medicinal chemistry and drug discovery due to its structural flexibility and synthetic utility.

InChI:InChI=1/C11H10N4/c12-6-10-8-15(14-11(10)13)7-9-4-2-1-3-5-9/h1-5,8H,7H2,(H2,13,14)

Upstream product

• 100-44-7 benzyl chloride 
• 16617-46-2 3-amino-4-cyano-2H-pyrazole 
• 20570-96-1 benzylhydrazine dihydrochloride 
• 123-06-8 Ethoxymethylenemalononitrile 
• 16617-46-2 3-Amino-4-cyanopyrazole 
• 100-39-0 benzyl bromide 

Downstream Products

• 122800-04-8 1-Benzyl-3-(4-fluoro-2-nitro-phenylamino)-1H-pyrazole-4-carbonitrile 
• 66077-23-4 C₁₁H₈N₄O₂ 
• 1380347-91-0 tert-butyl [(5S)-2-benzyl-7-hydroxy-6-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-5-yl]carbamate 
• 1380347-90-9 2,2,2-trifluoroethyl 3-(1-benzyl-3-nitro-1H-pyrazol-4-yl)-N-(tert-butoxycarbonyl)-L-alaninate 
• 1380349-00-7 (5S)-5-amino-2-benzyl-7-hydroxy-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one 
• 1380347-88-5 3-(1-benzyl-3-nitro-1H-pyrazol-4-yl )-N-(tert-butoxycarbonyl )-Lalanine 
• 1380481-72-0 C₁₃H₁₄N₄O₄ 
• 1380347-84-1 tert-butyl 3-(1-benzyl-3-nitro-1H-pyrazol-4-yl)-N-(diphenylmethylene)-L-alaninate 
• 1380347-82-9 1-benzyl-4-(bromomethyl)-3-nitro-1H-pyrazole 
• 1380347-81-8 (1-benzyl-3-nitro-1H-pyrazol-4-yl)methanol 
• 1428734-00-2 C₁₁H₉N₃O₄ 
• 1224256-32-9 C₁₈H₁₅N₅ 
• 122821-42-5 2-Benzyl-7-fluoro-10-(4-methyl-piperazin-1-yl)-2,4-dihydro-2,3,4,9-tetraaza-benzo[f]azulene 
• 56156-22-0 5-amino-1-benzyl-1H-pyrazole-4-carboxylic acid amide 

Relevant articles and documents

AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies

This study reports the synthesis of a number of 1- and 2-alkyl derivatives of the 4-aminopyrazolo[3,4-d]pyrimidine (APP) nucleus and their evaluation as inhibitors of ADA from bovine spleen. The 2-substituted aminopyrazolopyrimidines proved to be potent inhibitors, most of them exhibiting Ki values in the nanomolar/subnanomolar range. In this series the inhibitory activity is enhanced with the increase in length of the alkyl chain, reaching a maximum with the n-decyl substituent. Insertion of a 2′-hydroxy group in the ra-decyl chain gave 3k, whose (R)-isomer displayed the highest inhibitory potency of the series (Ki 0.053 nM), showing an activity 2 orders of magnitude higher than that of (+)-EHNA (Ki 1.14 nM), which was taken as the reference standard. Docking simulations of aminopyrazolopyrimidines into the ADA binding site were also performed, to rationalize the structure-activity relationships of this class of inhibitors.

Adenosine A3 receptor modulators

The compounds of the following formula: wherein R, R2, R3 and A have the meanings given in the specification, are endowed with selective A3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceu